115 related articles for article (PubMed ID: 17724700)
1. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
Darbari DS; van Schaik RH; Capparelli EV; Rana S; McCarter R; van den Anker J
Am J Hematol; 2008 Mar; 83(3):200-2. PubMed ID: 17724700
[TBL] [Abstract][Full Text] [Related]
2. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.
Holthe M; Rakvåg TN; Klepstad P; Idle JR; Kaasa S; Krokan HE; Skorpen F
Pharmacogenomics J; 2003; 3(1):17-26. PubMed ID: 12629580
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of morphine: Potential implications in sickle cell disease.
Darbari DS; Minniti CP; Rana S; van den Anker J
Am J Hematol; 2008 Mar; 83(3):233-6. PubMed ID: 17722074
[TBL] [Abstract][Full Text] [Related]
4. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
5. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
Duguay Y; Báár C; Skorpen F; Guillemette C
Clin Pharmacol Ther; 2004 Mar; 75(3):223-33. PubMed ID: 15001974
[TBL] [Abstract][Full Text] [Related]
6. The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ; Li L; Wang L; Yuan LM; Xu MC; Gu JK; Jiang HD; Yu LS; Zeng S
Acta Pharmacol Sin; 2017 Aug; 38(8):1184-1194. PubMed ID: 28552915
[TBL] [Abstract][Full Text] [Related]
7. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
[TBL] [Abstract][Full Text] [Related]
8. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.
Fisher MB; Vandenbranden M; Findlay K; Burchell B; Thummel KE; Hall SD; Wrighton SA
Pharmacogenetics; 2000 Nov; 10(8):727-39. PubMed ID: 11186135
[TBL] [Abstract][Full Text] [Related]
9. Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics.
Nielsen LM; Sverrisdóttir E; Stage TB; Feddersen S; Brøsen K; Christrup LL; Drewes AM; Olesen AE
Eur J Pharm Sci; 2017 Mar; 99():337-342. PubMed ID: 28063968
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects.
Chung JY; Cho JY; Yu KS; Kim JR; Lim KS; Sohn DR; Shin SG; Jang IJ
Clin Pharmacol Ther; 2008 Apr; 83(4):595-600. PubMed ID: 17687269
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
Innocenti F; Liu W; Fackenthal D; Ramírez J; Chen P; Ye X; Wu X; Zhang W; Mirkov S; Das S; Cook E; Ratain MJ
Pharmacogenet Genomics; 2008 Aug; 18(8):683-97. PubMed ID: 18622261
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance.
Bhasker CR; McKinnon W; Stone A; Lo AC; Kubota T; Ishizaki T; Miners JO
Pharmacogenetics; 2000 Nov; 10(8):679-85. PubMed ID: 11186130
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
Ramírez J; Liu W; Mirkov S; Desai AA; Chen P; Das S; Innocenti F; Ratain MJ
Drug Metab Dispos; 2007 Dec; 35(12):2149-53. PubMed ID: 17761781
[TBL] [Abstract][Full Text] [Related]
14. Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor.
Yang ZZ; Li L; Xu MC; Ju HX; Hao M; Gu JK; Jim Wang ZJ; Jiang HD; Yu LS; Zeng S
Oncotarget; 2017 Apr; 8(17):29138-29150. PubMed ID: 28418861
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability and clinical efficacy of morphine.
Klepstad P; Dale O; Skorpen F; Borchgrevink PC; Kaasa S
Acta Anaesthesiol Scand; 2005 Aug; 49(7):902-8. PubMed ID: 16045647
[TBL] [Abstract][Full Text] [Related]
16. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age.
Allegaert K; Vanhaesebrouck S; Verbesselt R; van den Anker JN
Ther Drug Monit; 2009 Aug; 31(4):411-5. PubMed ID: 19494793
[TBL] [Abstract][Full Text] [Related]
17. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis.
Callaghan R; Desmond PV; Paull P; Mashford ML
Hepatology; 1993 Jul; 18(1):54-60. PubMed ID: 8325621
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.
Shord SS; Cavallari LH; Gao W; Jeong HY; Deyo K; Patel SR; Camp JR; Labott SM; Molokie RE
Eur J Clin Pharmacol; 2009 Jul; 65(7):651-8. PubMed ID: 19357842
[TBL] [Abstract][Full Text] [Related]
19. Increased clearance of morphine in sickle cell disease: implications for pain management.
Darbari DS; Neely M; van den Anker J; Rana S
J Pain; 2011 May; 12(5):531-8. PubMed ID: 21277838
[TBL] [Abstract][Full Text] [Related]
20. Chronic ethanol consumption causes increased glucuronidation of morphine in rabbits.
Narayan SS; Hayton WL; Yost GS
Xenobiotica; 1991 Apr; 21(4):515-24. PubMed ID: 1910230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
